Project Grant P50CA295495
Award Date 9/5/25
Completion Date 8/31/30
Dollars Obligated $2.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) totaling $2,876,456 will support the development of a strategy for hepatocellular carcinoma (HCC) risk assessment in cirrhosis and non-cirrhosis patients with major viral and metabolic etiologies, as well as resources for cholangiocarcinoma (CCA) risk biomarkers. The grant will be used by the University of Texas Southwestern Medical Center to build upon their previously developed...
- This Project Grant award of $306,739.00, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to improve treatment outcomes for patients with hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. The research focuses on identifying the most effective inhibitors of the enzyme ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) in HCC models. ENPP1 plays a key role in suppressing the immune response against HCC...
- This $521,579 Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research to identify critical regulators controlling clear cell renal cell carcinoma (CCRCC) lung metastasis. The University of Texas Southwestern Medical Center, the awardee, will conduct a genome-wide CRISPR screen to characterize the role of the hepatic leukemia factor (HLF) in CCRCC lung metastasis and examine the underlying molecular...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support research at the University of Texas MD Anderson Cancer Center to develop mathematical models and computational tools for optimizing the delivery of a transarterial ablative therapy for treating hepatocellular carcinoma (liver cancer). The $536,836 award will fund a multi-disciplinary research effort to formulate mathematical models that capture the complex physical and...
- The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $449,196 federal Project Grant by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant, effective from April 1, 2025 to March 31, 2030, will support research aimed at understanding the mechanisms of resistance to tyrosine kinase inhibitor (TKI) therapies in cancer, with a focus on EGFR mutant non-small cell lung cancer (NSCLC) and other activated receptor...
- This $421,685 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Texas MD Anderson Cancer Center supports research to investigate how the LIFR-LCN2 pathway in liver cancer restricts the cytotoxic function of CD8+ T cells, leading to immune evasion and resistance to immunotherapy. The central hypothesis is that loss of LIFR upregulates LCN2 in liver cancer, thereby suppressing the abundance and cytotoxic function of CD8+...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $399,966 in funding to Cloverleaf Bio, Inc. to advance the pre-clinical development of a novel therapeutic approach for treating hepatocellular carcinoma (HCC), the most common form of liver cancer. The key objectives are to: (1) develop additional in vitro-optimized therapeutic transfer RNAs (tRNAs) containing the chemotherapeutic agent 5-fluorouracil (5-FU) to target multiple...
- This federal Project Grant award of $270,981 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports a five-year research program to investigate resistance mechanisms to anti-PD-1/L1 immunotherapy in hepatobiliary cancers. The key objectives are to: Conduct a Phase 2 trial evaluating an anti-TIGIT plus anti-PD-1 antibody combination in hepatobiliary cancers refractory to PD-1 blockade. Characterize immune and molecular features of anti-PD-1/L1 therapy-resistant...
- The National Cancer Institute (NCI) awarded a $793,324 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope to develop selective small molecule inhibitors targeting the CYP8B1 enzyme as a novel approach to treat hepatocellular carcinoma (HCC), including metabolic dysfunction-associated HCC. The project aims to discover and validate CYP8B1 inhibitors that may provide a unique pharmacological therapy for HCC, which is the...
- The Project Grant award of $300,000.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support a study on the epidemiology of the gut-liver axis and its relationship to hepatocellular carcinoma (HCC) risk in a multiethnic liver cirrhosis cohort. The study aims to expand the existing Microbiome, Microbial Markers, and Liver Disease (M3LD) cohort by enrolling approximately 1,000 participants with liver cirrhosis, with a focus on...